Bortezomib is a selective and robust 26S proteasome inhibitor, that is a boronic acid dipeptide derivative. Human pancreatic cancer cell studies demonstrate Bortezomib to inhibit the PKR-like endoplasmic reticulum (ER) kinase and enhance ER stress, leading to apoptosis. Studies suggest that Bortezomib affects the gene expression of WT1, and blocks the function of human plasmacytoid DCs through the inhibition of intracellular trafficking of Toll-like receptors and modification of the ER homeostasis. Additionally, Bortezomib has been reported to inhibit necrosis and cell proliferation, and downregulate metastatic gene expression. Bortezomib is an inhibitor of 20S Proteasome.
1. Lightcap, E.S. et al. 2000. Clin. Chem. 46(5): 673-683. PMID: 10794750
2. Adams, J. 2002. Oncologist. 7(1): 9-16. PMID: 11854543
3. Ling, Y.H. et al. 2003. Clin. Cancer Res. 9(3): 1145-1154. PMID: 12631620
5. Nawrocki, S.T., et al. 2005. Cancer Res. 65: 11510-11519. PMID: 16357160
6. Hirai, M., et al. 2010. Blood. [Epub ahead of print]. PMID: 20956804
7. Jones, M.D., et al. 2010. Clin. Cancer Res. 16: 4978-4989. PMID: 20843837
8. Alimena, G., et al. 2010. Leuk Res. [Epub ahead of print]. PMID: 20971509
9. Dou, Q.P. and Zonder, J.A. 2014. Curr Cancer Drug Targets. 14(6): 517-536. PMID: 25092212
Ver como otros han utilizado Bortezomib (CAS 179324-69-7). Haga click en la entrada de PubMed .
PMID: # 31015476 Lübbehüsen, C. et al. 2019. Sci Rep. 9: 6458.
PMID: # 31399560 Willbold, R.|Wirth, K.|Martini, T.|Sültmann, H.|Bolenz, C.|Wittig, R.| et al. 2019. Cell Death Dis. 10: 601.
PMID: # 31257577 Gomez-Puerto, MC. et al. 2019. J. Pathol.
PMID: # 29543923 Kocemba-Pilarczyk, KA.|Ostrowska, B.|Trojan, S.|Aslan, E.|Kusior, D.|Lasota, M.|Lenouvel, C.|Dulińska-Litewka, J.| et al. 2018. Acta Biochim. Pol. 65: 101-109.
PMID: # 29599781 Tucher, C.|Bode, K.|Schiller, P.|Claßen, L.|Birr, C.|Souto-Carneiro, MM.|Blank, N.|Lorenz, HM.|Schiller, M.| et al. 2018. Front Immunol. 9: 534.
PMID: # 30586869 Granato, M.|Gilardini Montani, MS.|Angiolillo, C.|D'Orazi, G.|Faggioni, A.|Cirone, M.| et al. 2018. Viruses. 11:
PMID: # 30224516 Alsanafi, M.|Kelly, SL.|Jubair, K.|McNaughton, M.|Tate, RJ.|Merrill, AH.|Pyne, S.|Pyne, NJ.| et al. 2018. Mol. Cell. Biol. 38:
PMID: # 29462804 Qin, XY. et al. 2018. Cell. Physiol. Biochem. 45: 1366-1376.
PMID: # 29669822 Song, X.|Lee, DH.|Dilly, AK.|Lee, YS.|Choudry, HA.|Kwon, YT.|Bartlett, DL.|Lee, YJ.| et al. 2018. Mol. Cancer Res. 16: 1077-1091.
PMID: # 28883123 Londino, JD. et al. 2017. The Biochemical journal. 474: 3543-3557.
Santa Cruz Biotechnology, Inc. es un líder mundial en el desarrollo de productos para el mercado de la investigación biomédica. Llámenos gratis al 00 800 4573 8000.
Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. All Rights Reserved."Santa Cruz Biotechnology", y el logo de Santa Cruz Biotechnology, Inc., "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", el logo de San Juan Ranch, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", y "EZ Touch" son marcas registradas de Santa Cruz Biotechnology, Inc. Todas las marcas registradas son propiedad de su respectivo dueño.